hyperCORE International Strengthens Leadership Team with New Vice President and Treasurer Appointments

hyperCORE International, a leading collaborative network of clinical trial sites across North America, has announced significant updates to its executive leadership team with the appointment of Jeffrey Smyth as Vice President and Olivia McIver as Treasurer. These strategic additions strengthen the organization's governance structure and ensure continued alignment with hyperCORE's mission of driving efficiency and excellence across its collective partner site networks.

Jeffrey Smyth, who serves as President and Executive Director of partner site network TrueBlue Clinical Research, brings extensive leadership experience to his new role as Vice President. Olivia McIver, currently Director of Clinical Operations at partner site network Applied Research Center, assumes the Treasurer position. In their new executive capacities, Smyth and McIver will provide complementary expertise to support hyperCORE's continued growth and play crucial roles in overseeing financial stewardship while supporting long-term sustainability objectives.

The leadership expansion comes as hyperCORE continues to solidify its position as a major force in clinical research. The organization's partner site networks include AGA Clinical Trials; Alcanza Clinical Research; Apex Trials; Applied Research Center; Atlas Clinical Research; CaRe Clinics; Epic Medical Research; FOMAT Medical Research; TrueBlue Clinical Research; and QCR Network. Each independently operated network participates in harmonized operational frameworks that streamline study delivery at scale.

Nicholas Focil, President of hyperCORE, emphasized the strategic importance of these appointments. "hyperCORE's strength lies in its ability to unify best-in-class research sites through shared operational excellence," Focil stated. "As we continue to grow, having a dedicated and strategic Vice President and integrated board Treasurer is essential to guide our leadership framework and maintain our strategic mobility across our industry."

The leadership team restructuring maintains continuity with existing executives. Nicholas Focil, who also serves as CEO of FOMAT Medical Research, will continue in his role as President, while Mark Scullion, CEO of Atlas Clinical Research, remains as Secretary. This experienced leadership combination provides trusted guidance for hyperCORE's next phase of growth and expansion.

hyperCORE International represents a significant force in clinical research, boasting over 80 active trial sites across five countries and two continents. The organization's partners have collectively completed more than 7,500 studies involving over 150,000 randomized participants. The network's collaborative approach allows independent partner members to maintain operational autonomy while integrating harmonized frameworks that optimize efficiency, standardization, and excellence across all research activities.

The enhanced leadership structure positions hyperCORE to continue advancing clinical research through safe, ethical, and timely studies while maintaining efficient enrollment and superior retention rates. The organization's commitment to excellence is further demonstrated by its members' consistent recognition with top-tier awards for performance, quality, and innovation in clinical research. These executive appointments signal hyperCORE's ongoing dedication to strengthening its governance and operational capabilities as it navigates the evolving landscape of clinical trial research.